Portfolio News
- February 25, 2013 Durata Therapeutics Announces Preliminary, Topline Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI
- February 04, 2013 - BioWorld TodayBulls Proved Right: Hyperion's Ravicti Wins Approval in UCD
- January 31, 2013 KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
- January 31, 2013 Amarin Announces Notification of Two Additional Patent Allowances for U.S. Applications (13/458,496 and 13/349,157) Related to Vascepa(R) and FDA Approved MARINE Indication
- January 25, 2013 KaloBios on path toward $50 million IPO
- January 22, 2013 Cortina's New 15G CDR and Backplane PHY Leads Industry in Performance, Density and Low Power
- January 17, 2013 Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Spain For The Treatment Of Chronic Diabetic Macular Edema
- January 10, 2013 Guavus raises $30 million for data analytics
- January 08, 2013 CrestaTech Announces 4th Generation Smart Tuner; TheX7 for Flat Panel TVs
- January 07, 2013 CrestaTech Enhances Management, Prepares to Launch Variety of Smart Tuner Products in New Year
- January 03, 2013 Labrys Biologics Secures $31 Million Series A Financing from Venture Capital Firms; Acquires Phase 2 Ready Antibody for Chronic Migraine from Pfizer
- December 04, 2012 Salveo Specialty Pharmacy, Inc.Completes Additional Equity and Debt Financings
and Acquisition of Mission Road Pharmacy
- November 26, 2012 Amarin Announces Notification of Patent Allowance for U.S. Application 13/610,247 Related to Vascepa(R) and FDA Approved MARINE Indication
- October 24, 2012 Mirna Therapeutics Secures $34.5 Million Series C Financing
to Advance Oncology microRNA Pipeline into the Clinic
- October 23, 2012 Amarin Announces Issuance of U.S. Patents 8,793,727 and 8,293,728 for Vascepa(TM)
Issuances for '889 and '153 Applications
< More recent articles | Past articles >
Events
- October 28, 2013Mike Powell, BioNetwork West 2013 - "The Outlook for Traditional Venture Capital Firms: Evolving Trends and Opportunities"
- October 22, 2013Sofinnova Japan BioPharma Partnering Conference
- June 18, 2013Jennifer James, 2013 PEI Investor Relations Forum "Fundraising the next generation"
- March 25, 2013Mike Powell, Lecture at UCSF - "Lessons Learned in Venture Capital: What I learned the Hard Way, the Easy Way, and from the Entrepreneurs"
- February 12, 2013Anand Mehra Presents to Bio2Device Group
Media Contact
Jennifer James
VP of Marketing and Investor Relations
Sofinnova Ventures
jennifer@sofinnova.com
(650) 681-8429
